Covered recipient · General Payments record
GERALD DRYDEN
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2020 · Entire year
$155,324.01
97 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2020 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $124,580.00 | 50 |
| Travel and Lodging | $11,448.19 | 16 |
| Consulting Fee | $10,025.00 | 4 |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $7,800.00 | 2 |
| Food and Beverage | $1,470.82 | 25 |
By paying entity
PY2020 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Janssen Scientific Affairs, LLC | $65,130.17 | 37 |
| Takeda Pharmaceuticals U.S.A., Inc. | $46,349.60 | 27 |
| AbbVie Inc. | $20,985.73 | 22 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $7,800.00 | 2 |
| Lilly USA, LLC | $7,200.00 | 1 |
| PFIZER INC. | $6,120.66 | 5 |
| Janssen Biotech, Inc. | $1,725.00 | 2 |
| GE HEALTHCARE | $12.85 | 1 |
Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
GERALD DRYDEN
NPI 1619969011 · CMS profile ID 299994
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
LOUISVILLE, KY
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1619969011?year=2020&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- GERALD DRYDEN, NPI 1619969011, CMS profile ID 299994. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1619969011?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- APA 7
- IndustryPayments. (2026). GERALD DRYDEN, NPI 1619969011, CMS profile ID 299994. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1619969011?year=2020&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
- Bluebook
- GERALD DRYDEN, NPI 1619969011, CMS profile ID 299994, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1619969011?year=2020&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2020
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30
97 matching records · $155,324.01 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–97 of 97.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $168.72 | 03/04/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747156691 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $55.49 | 03/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 747156693 | CMS |
| Janssen Scientific Affairs, LLC | $71.75 | 03/03/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719153017 | CMS |
| Janssen Scientific Affairs, LLC | $909.93 | 03/03/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719153019 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,475.00 | 02/26/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753936424 | CMS |
| Janssen Scientific Affairs, LLC | $4,025.00 | 02/18/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719153013 | CMS |
| Janssen Scientific Affairs, LLC | $77.49 | 02/15/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719153007 | CMS |
| Janssen Scientific Affairs, LLC | $1,062.52 | 02/15/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719153009 | CMS |
| PFIZER INC. | $2,625.00 | 02/13/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743119807 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $31.60 | 02/12/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753936420 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $978.80 | 02/12/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 753936422 | CMS |
| Janssen Scientific Affairs, LLC | $4,025.00 | 02/11/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719153011 | CMS |
| PFIZER INC. | $14.79 | 02/11/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743109897 | CMS |
| Janssen Scientific Affairs, LLC | $110.98 | 02/05/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152997 | CMS |
| Janssen Scientific Affairs, LLC | $2,575.00 | 02/04/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152999 | CMS |
| Janssen Scientific Affairs, LLC | $4,025.00 | 02/04/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719153001 | CMS |
| Janssen Scientific Affairs, LLC | $4,025.00 | 02/04/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719153003 | CMS |
| Janssen Scientific Affairs, LLC | $118.12 | 02/04/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719153005 | CMS |
| Janssen Scientific Affairs, LLC | $860.00 | 01/31/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152969 | CMS |
| Janssen Scientific Affairs, LLC | $124.99 | 01/30/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152991 | CMS |
| Janssen Scientific Affairs, LLC | $1,040.07 | 01/30/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152993 | CMS |
| AbbVie Inc. | $2,612.50 | 01/29/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721757815 | CMS |
| AbbVie Inc. | $1,787.50 | 01/29/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721757817 | CMS |
| Janssen Scientific Affairs, LLC | $2,059.02 | 01/29/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152983 | CMS |
| Janssen Scientific Affairs, LLC | $76.20 | 01/29/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152987 | CMS |
| Janssen Scientific Affairs, LLC | $4,025.00 | 01/28/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152985 | CMS |
| Janssen Scientific Affairs, LLC | $2,575.00 | 01/28/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152989 | CMS |
| Janssen Scientific Affairs, LLC | $4,025.00 | 01/28/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152995 | CMS |
| GE HEALTHCARE | $12.85 | 01/27/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 743988057 | CMS |
| AbbVie Inc. | $51.11 | 01/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721757807 | CMS |
| AbbVie Inc. | $15.51 | 01/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721757809 | CMS |
| AbbVie Inc. | $11.78 | 01/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721757811 | CMS |
| AbbVie Inc. | $23.04 | 01/26/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721757813 | CMS |
| AbbVie Inc. | $63.13 | 01/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721757795 | CMS |
| AbbVie Inc. | $33.22 | 01/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721757797 | CMS |
| AbbVie Inc. | $9.57 | 01/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721757799 | CMS |
| AbbVie Inc. | $11.04 | 01/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721757801 | CMS |
| AbbVie Inc. | $120.44 | 01/25/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721757803 | CMS |
| AbbVie Inc. | $296.89 | 01/25/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 721757805 | CMS |
| Janssen Scientific Affairs, LLC | $31.99 | 01/23/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152977 | CMS |
| Janssen Scientific Affairs, LLC | $863.63 | 01/23/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152979 | CMS |
| Janssen Scientific Affairs, LLC | $4,025.00 | 01/22/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152975 | CMS |
| Janssen Scientific Affairs, LLC | $4,025.00 | 01/22/2020 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152981 | CMS |
| Janssen Scientific Affairs, LLC | $123.05 | 01/21/2020 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152971 | CMS |
| Janssen Scientific Affairs, LLC | $1,280.43 | 01/21/2020 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 719152973 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $2,800.00 | 01/06/2020 | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737517925 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $5,000.00 | 01/03/2020 | Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 737517923 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $243,923.83 | 62 |
| PY2024 | Principal investigator | $282,774.63 | 62 |
| PY2023 | Recipient | $6,475.00 | 2 |
| PY2023 | Principal investigator | $170,256.86 | 37 |
| PY2022 | Recipient | $1,583.00 | 2 |
| PY2022 | Principal investigator | $114,610.64 | 34 |
| PY2021 | Recipient | $272.46 | 2 |
| PY2021 | Principal investigator | $92,771.18 | 38 |
| PY2020 | Recipient | $1,168.03 | 1 |
| PY2020 | Principal investigator | $237,501.02 | 97 |
| PY2019 | Recipient | $3,092.63 | 3 |
| PY2019 | Principal investigator | $223,398.49 | 95 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
62 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $2,766.00 | 12/29/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222256 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,592.00 | 12/29/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222339 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $7,224.35 | 12/04/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223289198 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $13,829.00 | 11/10/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC | A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) | No dispute reported | 06/30/2026 | 1244052539 |
| Principal investigator 1 | ABBVIE INC. | $9,376.60 | 11/04/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202521035 |
| Principal investigator 1 | ABBVIE INC. | $237.00 | 11/04/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202521089 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,624.00 | 10/27/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222431 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,592.00 | 10/27/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222605 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,766.00 | 10/27/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222613 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,766.00 | 10/27/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222630 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,766.00 | 10/27/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222748 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,766.00 | 10/27/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222793 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,766.00 | 10/27/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222837 |
| Principal investigator 1 | ABBVIE INC. | $1,319.90 | 10/09/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202514109 |
| Principal investigator 1 | Janssen Research & Development, LLC | $712.00 | 09/24/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222209 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,847.00 | 09/24/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222415 |
| Principal investigator 1 | Janssen Research & Development, LLC | $712.00 | 09/24/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222424 |
| Principal investigator 1 | Janssen Research & Development, LLC | $822.00 | 09/24/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222762 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $9,135.75 | 09/23/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223285808 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $12,871.63 | 09/12/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223285307 |
| Principal investigator 1 | ABBVIE INC. | $1,319.90 | 09/03/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202507673 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,618.50 | 08/20/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222176 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,718.00 | 08/20/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222640 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,782.00 | 08/20/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222785 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,618.50 | 08/13/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222705 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,500.00 | 08/13/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222769 |
| Principal investigator 1 | ABBVIE INC. | $2,924.50 | 08/05/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202501654 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $11,131.20 | 08/01/2025 | Non-covered Recipient Entity University Of Louisville Research Foundation, Inc, | An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | No dispute reported | 06/30/2026 | 1235992533 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,624.00 | 07/28/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222201 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,788.00 | 07/28/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222356 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,209.00 | 07/28/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222368 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,766.00 | 07/28/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222567 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,766.00 | 07/28/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222649 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 07/28/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222692 |
| Principal investigator 1 | ABBVIE INC. | $4,290.00 | 07/02/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202495751 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,766.00 | 06/30/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222225 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,766.00 | 06/30/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222374 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,592.00 | 06/30/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222740 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,292.20 | 06/24/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223281796 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,531.00 | 06/24/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC | TAK-279-UC-2001 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative Colitis | No dispute reported | 06/30/2026 | 1223281798 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $1,292.20 | 06/12/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223281120 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $4,531.00 | 06/12/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION INC | A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneosly Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment due to Alzheimer's Disease (MCI due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI due to AD in Cognitively Normal Subjects | No dispute reported | 06/30/2026 | 1223281122 |
| Principal investigator 1 | ABBVIE INC. | $79.80 | 06/11/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202490873 |
| Principal investigator 1 | ABBVIE INC. | $3,209.20 | 06/03/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202488707 |
| Principal investigator 1 | ABBVIE INC. | $193.40 | 05/19/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION | A Study to Evaluate the Long-Term Efficacy Safety and Tolerability of Repeated Administration of Upadacitinib (ABT-494) in Participants With Crohn Disease | No dispute reported | 06/30/2026 | 1202485411 |
| Principal investigator 1 | ABBVIE INC. | $1,586.40 | 05/06/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE | A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202481427 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,312.00 | 04/28/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222301 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,532.00 | 04/28/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222347 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,312.00 | 04/28/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease (DUET-CD) | No dispute reported | 06/30/2026 | 1175222476 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,229.00 | 04/21/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222267 |
| Principal investigator 1 | Janssen Research & Development, LLC | $343.00 | 04/21/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222494 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,997.00 | 04/21/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222714 |
| Principal investigator 1 | Janssen Research & Development, LLC | $6,540.00 | 04/21/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222722 |
| Principal investigator 1 | ABBVIE INC. | $11,922.80 | 03/06/2025 | Non-covered Recipient Entity UNIVERSITY OF LOUISVILLE | M14-430 - A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn Disease Who Completed the Studies M14-431 or M14-433 | No dispute reported | 06/30/2026 | 1202457678 |
| Principal investigator 1 | Genentech, Inc. | $3,250.00 | 02/20/2025 | Non-covered Recipient Entity CLINICAL RESEARCH FOUNDATION INC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211587152 |
| Principal investigator 1 | Genentech, Inc. | $5,000.00 | 02/20/2025 | Non-covered Recipient Entity CLINICAL RESEARCH FOUNDATION INC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211587157 |
| Principal investigator 1 | Genentech, Inc. | $15,000.00 | 02/20/2025 | Non-covered Recipient Entity CLINICAL RESEARCH FOUNDATION INC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211587161 |
| Principal investigator 1 | Genentech, Inc. | $2,587.00 | 02/20/2025 | Non-covered Recipient Entity CLINICAL RESEARCH FOUNDATION INC | UC P3: Double-Blind Treat Straight Through | No dispute reported | 06/30/2026 | 1211587164 |
| Principal investigator 1 | Janssen Research & Development, LLC | $4,763.00 | 01/30/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222157 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,748.00 | 01/30/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222439 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,430.00 | 01/30/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222800 |
| Principal investigator 1 | Janssen Research & Development, LLC | $3,229.00 | 01/30/2025 | Non-covered Recipient Entity Univ Of Louisville Rsrch Fndtn Inc. | A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis (DUET-UC) | No dispute reported | 06/30/2026 | 1175222823 |